PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.98%
Revenue growth 1.25-1.5x AVGO's 6.32%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
49.12%
Gross profit growth above 1.5x AVGO's 4.96%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
241.17%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
241.17%
Operating income growth above 1.5x AVGO's 1.00%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
204.73%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
196.15%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
196.15%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
9.26%
Share count expansion well above AVGO's 0.15%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
9.26%
Diluted share count expanding well above AVGO's 0.70%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
36.23%
OCF growth above 1.5x AVGO's 9.32%. David Dodd would confirm a clear edge in underlying cash generation.
31.32%
FCF growth above 1.5x AVGO's 9.56%. David Dodd would verify if the firm’s strategic investments yield superior returns.
227.44%
10Y revenue/share CAGR at 50-75% of AVGO's 416.86%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
227.44%
5Y revenue/share CAGR above 1.5x AVGO's 134.28%. David Dodd would look for consistent product or market expansions fueling outperformance.
227.44%
3Y revenue/share CAGR above 1.5x AVGO's 62.33%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
2003.06%
10Y OCF/share CAGR above 1.5x AVGO's 580.47%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
2003.06%
5Y OCF/share CAGR above 1.5x AVGO's 92.77%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
2003.06%
3Y OCF/share CAGR above 1.5x AVGO's 39.51%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
212.78%
Below 50% of AVGO's 869.72%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
212.78%
5Y net income/share CAGR at 50-75% of AVGO's 414.43%. Martin Whitman might see a shortfall in operational efficiency or brand power.
212.78%
3Y net income/share CAGR above 1.5x AVGO's 16.00%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
571.10%
10Y equity/share CAGR at 50-75% of AVGO's 862.23%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
571.10%
5Y equity/share CAGR above 1.5x AVGO's 165.61%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
571.10%
3Y equity/share CAGR above 1.5x AVGO's 201.93%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.10%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-29.26%
Inventory is declining while AVGO stands at 8.08%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-0.78%
Negative asset growth while AVGO invests at 0.60%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-2.92%
We have a declining book value while AVGO shows 5.15%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.44%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-0.70%
Our R&D shrinks while AVGO invests at 13.26%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
145.70%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.